Wildix Rolls out Fully Embedded Agentic AI for UCaaS that's Modular, Codeless, Autonomous
TALLINN, Estonia--(BUSINESS WIRE)--Wildix, a global Unified Communications as a Service (UCaaS) provider, today announced the launch of the industry's first fully embedded agentic AI layer for UCaaS, now operational across more than 1,000 customer environments.
"Our AI doesn't just assist. It executes, adapts and integrates natively into existing workflows with zero" said Dimitri Osler, co-founder and CIO, Wildix.
Share
Designed to adapt to how each organization operates, the AI layer automates interactions across voice, chat, SMS, WhatsApp and web, without relying on static scripts or bolted-on bots. The system interprets language, references past exchanges and applies contextual logic to guide each decision.
Modular by design, the system can be tailored to specific workflows, whether it's routing calls in public services, handling appointments in healthcare or managing surges in retail. Configuration happens through a visual no-code studio, making deployment fast, repeatable and scalable for partners and customers alike.
According to Gartner, agentic AI will autonomously resolve 80% of customer service issues by 2029, leading to a 30% reduction in operational costs.
'Wildix's launch of its agentic AI solution that works across all types of communication channels is very timely,' said Oru Mohiuddin, Research Director, IDC. 'Businesses are increasingly looking to automate workflows that can help to drive customer satisfaction and efficiency simultaneously. Solutions that can help to achieve this will resonate closely with customer demand.'
Wildix brings that future forward, with contextual automation, shared memory, and no-code design that deliver ROI from day one. It reduces overflow, speeds up response and proves its value from the start.
'Organizations are under pressure to accelerate service, reduce costs and improve responsiveness,' said Dimitri Osler, co-founder and CIO, Wildix. 'This release is designed to meet those expectations immediately. Our AI doesn't just assist. It executes, adapts and integrates natively into existing workflows with zero disruption.'
Core Capabilities That Support Business Outcomes
Wildix AI automates the high-frequency, high-friction tasks that slow teams down — scheduling, call routing, follow-ups and FAQs, while maintaining full context across every interaction.
Key capabilities include:
Codeless AI studio to launch expert workflows in minutes
Multilingual support in 13+ languages, across voice and chat
Sentiment-aware escalation to route complex or emotional cases to humans
Native integrations with Salesforce, HubSpot, WhatsApp, and Make.com
Omnichannel deployment, including browser, mobile, headsets and embeddable widgets
Persistent memory across agents, channels and sessions
GDPR-aligned architecture with transcription engines separated from LLMs to protect PII
The system is available across the full Wildix suite, including x-bees for sales-oriented teams, x-hoppers for retail and Collaboration 7 for business operations.
Real-world automation, measurable impact
Wildix partners work directly with customers to define metrics before deployment, from first-contact resolution to overflow cost reduction, and configure automation to deliver visible, immediate value.
In the United Kingdom, a growing network of telehealth providers implemented the AI system across more than 40 dental practices to address peak-hour call volumes. Today, the AI receptionist handles scheduling, reminders and insurance queries, reducing third-party overflow costs and increasing billable appointment time.
'This is one of the cleanest ROIs we've ever delivered,' said Stewart Donnor, Global Head of Sales Engineering, Wildix. 'It cuts overflow costs, increases billable time and it gives clinics their front desk back.'
In Spain, the Valencian Football Federation uses Wildix AI to absorb seasonal surges in fan inquiries, including ticketing, schedules and match-day updates. The system handles tens of thousands of contacts during peak events, without requiring year-round staffing.
"We saw the demand was going to grow before it became a problem," said Jaime Mestre, IT Manager, Valencia Football Federation. "With Wildix and the support of our Wildix Leader Network Gold Partner, we've created a system that understands our members, responds instantly and gives our staff time to focus on what really matters."
Scalable AI Architecture for Long-Term Growth
Wildix has spent years building AI features designed for real business use cases, from live call summaries and multilingual support to headset-triggered in-store alerts and sales coaching. This latest release consolidates those innovations into a single automation layer that can scale without disrupting daily operations or introducing third-party complexity.
Upcoming enhancements include unified scoring to assess both AI and human agent performance, CRM-driven coaching with real-time next-best-action prompts, native WhatsApp automation with live handoff and expanded language support.
To explore Wildix's AI-powered solutions, visit www.wildix.com/ai-solutions
About Wildix
Wildix is a global provider of Unified Communications as a Service (UCaaS) solutions, designed to simplify business collaboration and drive measurable performance. With fully integrated telephony, video, messaging, and AI capabilities, Wildix helps organizations connect securely and effectively, whether in-office, hybrid, or frontline. Its vertical retail platform, x-hoppers, delivers instant, hands-free communication to staff on the move, improving customer experience and operational speed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
33 minutes ago
- Bloomberg
Odd Lots: The Secretive Chinese Chip Giant That Could Be Nvidia's Biggest Threat
Right now, Nvidia stock is back near its all-time highs, thanks to seemingly unquenchable demand for its AI chips. When it comes to profiting off of this boom, Nvidia's lead and lock-in looks almost unassailable. But there is one particular company that is clearly on the mind of CEO Jensen Huang, and that is Huawei. On this episode, we speak with Washington Post reporter Eva Dou, the author of the new book House of Huawei: The Secret History of China's Most Powerful Company. Her book explains how the historical development of Huawei is basically synonymous with the rise of modern China, having started early on in Shenzhen, when that was one of the few parts of the country where capitalism and free enterprise were allowed to take root. She discusses what the company does, how it became so strong, its links to the Chinese government, and how it emerged as a possible rival to Nvidia.
WIRED
43 minutes ago
- WIRED
Can AI be the Solution to Cost-Effective Healthcare?
AI presents clear benefits to our severely challenged healthcare systems—but how can we deliver a better future without an eye-watering cost? Health technology leader Philips is mapping a way forward for the sector. Global healthcare systems face challenges today that impose an enormous burden. It's a familiar litany of problems: Populations are aging; chronic diseases are rising; and as we know from recent history, infectious diseases can still have a devastating impact around the globe. All this piles incredible pressure onto nurses and doctors, with healthcare systems struggling to cope given the widespread shortage of trained staff. Add to this that healthcare costs are rising, and it's little wonder that countries around the globe are finding it tough to deliver the quality healthcare that the public demands. Policy makers know that the solution will involve the smart application of artificial intelligence (AI). It has a proven ability to improve diagnostic accuracy and enable the early detection of disease, while treatment plans for patients can be personalized and administrative tasks streamlined. AI can be used to improve diagnosis and treatment of people that have felt overlooked in the past, including women—who make up most of the population. Educational institutions that teach medicine are looking at how AI can be integrated into the training of future nurses and doctors. The potential of AI to deliver impactful solutions and improved patient care is therefore recognized, but can it be the cost solution for healthcare systems? Philips, which for many years has been at the forefront of developing medical products and services in areas including diagnostic imaging, ultrasound, and image-guided therapy has been exploring the use of AI to address these challenges. As Shez Partovi, Chief Innovation & Strategy Officer at Philips explains: 'With aging populations and longer waiting times for patients, we need to develop credible solutions. Philips has been harnessing AI to increase scan detection rates, lower the burden on staff, and improve diagnosis. Key to the future success of health systems is delivering value and creating partnerships for change.' Philips has identified the potential for AI to make cost effective changes both on the clinical and operational side of healthcare systems. Examples include streamlining workflows and operations, providing clinical insights, expanding access to patient care, and supporting personalized healthcare. The result enables clinicians to see more patients, diagnose disease earlier, and deliver higher quality of care. This leads to patients recovering faster and spending less time in hospital, making treatment cheaper, and lowering the cost of healthcare per patient. Yet AI on its own is not enough—Philips believes that the key lies in combining AI with the very human skills and experience that one will find in hospitals and clinics: 'The aim is to create solutions that integrate into the workflows of healthcare providers and people's daily health routines. Something must be done or we risk being the first generation facing a healthcare system worse than previous generations.' Another advantage we are seeing with the AI solutions that Philips can deliver is the ability to provide quality care from hospitals into homes, increasing access to vital care in a range of settings. This includes the ability to detect different types of heart issues early on, putting care in the hands of patients whilst clinicians can monitor issues and manage diagnoses more effectively. 'In our view, AI is about supporting healthcare providers in their daily decision making, improving operational efficiency so there can be more focus on patient care, and empowering the public to take more care of their own health and wellbeing.' AI makes it so much easier for healthcare professionals to access large sets of data, enabling quicker assessment and more personalized treatment. This results in follow-up actions that have more impact, enhancing the quality of care a patient is getting, and a better outcome for that patient. Healthcare leaders are turning to virtual care and AI-enabled innovation to address pressures in the sector such as workforce shortages, financial constraints, and growing demand. By using AI, they have turned an overload of information into meaningful insights that allow care providers to provide better care to more people. Going forward, Philips is helping to build the strategic partnerships that will enable AI to be rolled out in such a way that healthcare systems can truly deliver to patients, while preventing burnout among staff. The company is also fostering a culture among healthcare stakeholders where the benefits of AI are fully understood and the will to implement grows ever stronger. The genie is out of the bottle. Artificial Intelligence is poised to change health systems in countries around the world for the better by delivering cost effective solutions. But it needs buy-in and commitment from all healthcare stakeholders. They are invited to work with Philips to create a healthcare system fit for purpose in the 21st century.
Business Wire
an hour ago
- Business Wire
Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
OSAKA, Japan & BOSTON--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; 'Ono') and Vertex Pharmaceuticals Incorporated (Headquarters: Boston, MA, U.S.; CEO: Reshma Kewalramani, M.D.; 'Vertex') today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex's povetacicept in Japan and South Korea. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best-in-class potential being studied for the treatment of immunoglobulin A nephropathy (IgAN), primary membranous nephropathy (pMN) and other serious B cell-mediated diseases. Under the terms of the agreement, Ono will pay Vertex an upfront payment, as well as certain regulatory and commercial milestone payments and tiered royalties. Ono will utilize its extensive development expertise to help advance Vertex's clinical trials for povetacicept and will be responsible for obtaining marketing authorizations in Japan and South Korea. Following approval, Ono will be solely responsible for commercializing povetacicept in these regions. The agreement includes povetacicept for both IgAN and pMN, with the potential to add other indications. 'Vertex has a strong track record of developing innovative therapies for serious diseases. Through this strategic partnership, we can strengthen our late-stage pipeline in the immunology field, which is a key focus area for Ono,' said Toichi Takino, Representative Director, President and Chief Operating Officer of Ono. 'We look forward to collaborating with Vertex to provide this new therapeutic option for patients with IgAN and other autoimmune diseases in Japan and South Korea, and to maximize the value of this treatment.' 'Ono is a proven leader in Japan and South Korea, bringing established local relationships, infrastructure, and nephrology expertise that make them a perfect partner for Vertex as we look to deliver povetacicept to the thousands of potential patients in these countries,' said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. 'We are very pleased to partner with Ono and look forward to close collaboration as we continue to advance this potentially best-in-class treatment for IgAN, pMN and other serious B cell-mediated diseases.' About Povetacicept Povetacicept is a recombinant fusion protein therapeutic and a dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, which play key roles in pathogenesis of multiple autoimmune diseases via their roles in the activation, differentiation, and/or survival of B cells, T cells, and innate immune cells. Based upon an engineered TACI (transmembrane activator and calcium modulator ligand interactor) domain, povetacicept has higher binding affinity and greater potency in preclinical studies versus other inhibitors of BAFF and/or APRIL alone and has demonstrated potential best-in-class efficacy in a clinical trial in patients with IgA nephropathy and primary membranous nephropathy. Povetacicept is also in development for multiple serious B cell-mediated diseases including other autoimmune kidney diseases and autoimmune cytopenias. About IgA Nephropathy (IgAN) IgAN is a serious, progressive, life-threatening, B cell-mediated chronic kidney disease that is the most common cause of primary (idiopathic) glomerulonephritis, affecting approximately 300,000 people in the United States and Europe. It is estimated that there are approximately 33,000 diagnosed patients in Japan. IgAN results from deposition of circulating immune complexes consisting of immunoglobulins and galactose-deficient immunoglobulin A (Gd-IgA1) in the renal glomerular mesangium, triggering kidney injury and fibrosis. Up to 72% of adult IgAN patients progress to end-stage renal disease within 20 years. There are no approved therapies that specifically target the underlying cause of IgAN. About Primary Membranous Nephropathy (pMN) Primary membranous nephropathy is a serious, progressive, life-threatening B cell-mediated chronic kidney disease affecting people worldwide, with approximately 150,000 people diagnosed in the U.S. and Europe. It is estimated that there are approximately 6,000 diagnosed patients with pMN in Japan. pMN is a rare glomerular disease that occurs when the body generates an abnormal immune response, including autoantibodies, against proteins that are part of the kidney. Autoantibodies trigger damage and inflammation, especially within the glomeruli (the parts of the kidney that filter blood), impairing the kidneys' ability to properly filter waste and fluid, eventually causing progressive loss of kidney function. There are no approved therapies that specifically target the underlying cause of pMN. About RAINIER RAINIER is a global Phase 3 pivotal trial of povetacicept 80 mg vs. placebo on top of standard of care in approximately 480 people with IgAN. The study is designed to have a pre-planned interim analysis evaluating urine protein to creatinine ratio (UPCR) for the povetacicept arm versus placebo after a certain number of patients reach 36 weeks of treatment. If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval in the U.S. Final analysis will occur at two years of treatment, with a primary endpoint of total eGFR slope through Week 104. The Phase 3 clinical trial is underway in multiple regions, including the U.S., EU and Asia. Specifically, Japanese and South Korean regulatory authorities have approved the Clinical Trial Application (CTA) for RAINIER, where the Phase 3 trial is underway. About RUBY-3 RUBY-3 is an ongoing, multiple ascending dose, multi-cohort, open label, Phase 1/2 basket study of povetacicept in autoimmune glomerulonephritis, including IgAN, primary membranous nephropathy, lupus nephritis, and ANCA-associated vasculitis with glomerulonephritis where povetacicept is being administered subcutaneously for up to 104 weeks. About Ono Pharmaceutical Co., Ltd Ono Pharmaceutical Co., Ltd. delivers innovative therapies for patients worldwide. Upholding its philosophy of 'Dedicated to the Fight against Disease and Pain,' Ono targets areas with unmet medical needs including oncology, immunology, and neurology, and fosters partnerships with academic and biotech organizations to accelerate drug discovery. Through its affiliate, Deciphera Pharmaceuticals, Ono is accelerating clinical development and commercial operations in the US and Europe to drive global business expansion and further its commitment to patient care. For more information, please visit the company's website at About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit or follow us on LinkedIn, Facebook, Instagram, YouTube and X. Ono Forward-Looking Statements In this press release, statements made with respect to current plans, estimates, strategies and beliefs, and other statements that are not historical facts are forward-looking statements about the future performance of the company. These statements are based on current assumptions and beliefs in light of the information currently available and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in the business environment in the pharmaceutical market and amendments to relevant laws and regulations, (ii) disruptions to product supply due to stagnation or delays in production caused by natural disasters, fires, etc., (iii) the possibility that sales activities for new and existing products may not achieve the expected results, (iv) the emergence of new side effects in post-marketing drugs, and (v) infringements of intellectual property rights by third parties. Information about pharmaceutical products included in this press release is not intended to constitute an advertisement or medical advice. Vertex Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements by Reshma Kewalramani M.D., and Toichi Takino, in this press release, and statements about the terms of and expectations for Vertex's collaboration with Ono, statements about potential benefits and results that may be achieved through the collaboration, statements regarding the future activities of the parties pursuant to the collaboration, including Ono's help to advance clinical trials and Ono's responsibility to obtain marketing authorizations in Japan and South Korea and to commercialize povetacicept in the regions, statements regarding upfront and milestone payments, and potential royalties on future products, and statements about Vertex's plans and expectations for the RAINIER and RUBY-3 clinical trials and potential plans to seek accelerated approval in the U.S. based on interim analysis from the RAINIER trial. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that the anticipated benefits and potential of the collaboration between Vertex and Ono may not be achieved on the anticipated timeline, or at all, that data may not support further development of the therapies subject to the collaboration due to safety, efficacy, or other reasons, and other risks listed under the heading 'Risk Factors' in Vertex's annual report filed with the Securities and Exchange Commission (SEC) and available through Vertex's website at and on the SEC's website at You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.
